PPV and NPV at deployment prevalence
Local prevalence adjustment.
What ppv and npv at deployment prevalence means
Local prevalence adjustment.
Why it matters. Predictive values depend on how common the condition is where you work.
A strong model has a low PPV in a low-prevalence screening clinic.
How to measure it
Gather local scans
Use scans from your own scanners and protocols.
Adjudicate labels
Radiologists agree the reference reading.
Test across sites and groups
Check scanners, sites and patient groups separately.
Check calibration
Compare predicted and observed rates.
Performance at the vendor's test site often doesn't hold at yours.
Local sensitivity and specificity with subgroup tables, external-site results and calibration.
Report local performance with radiologist-adjudicated labels, external sites, subgroup results and calibration, against a cleared comparator.
Reviewed by the Precision research team.
How strong is the evidence
E4 · Recalled, not verified. Recalled from background knowledge and not verified. Treat it as a lead for investigation, not a finding.
What the sources say
E4.
- Clinician judgement. Needs a clinician to judge or label, because the answer depends on clinical meaning.
- Real-world outcomes. Needs outcome data from live use, such as time saved, burnout or patient results.
Found something out of date? Write to hello@precision.example.
Agents that measure this
Quick answers
What is ppv and npv at deployment prevalence in healthcare AI?
Local prevalence adjustment. It sits in the imaging and diagnostics group.
Why does ppv and npv at deployment prevalence matter?
Predictive values depend on how common the condition is where you work. A strong model has a low PPV in a low-prevalence screening clinic.
How is ppv and npv at deployment prevalence measured?
Gather local scans, then Adjudicate labels, then Test across sites and groups, then Check calibration. Report local performance with radiologist-adjudicated labels, external sites, subgroup results and calibration, against a cleared comparator.
What should I watch out for with ppv and npv at deployment prevalence?
Performance at the vendor's test site often doesn't hold at yours. A good report gives: local sensitivity and specificity with subgroup tables, external-site results and calibration.
Can ppv and npv at deployment prevalence be automated?
Only in part. It needs clinician judgement and real-world outcomes. Software can screen, but a clinician must judge the cases that matter.